US spending will rise by 34%, reaching $560-590 billion
    The annual report, Global Medicines Use in 2020: Outlook and Implications, published by the IMS Institute for Healthcare Informatics, is out and available from the Institute. The bottom-line figures: From 2015 to 2020, global spending on pharmaceuticals will rise by 29-32%, to $1.4 trillion (it is estimated to come in at $1.068 billion when the books close on 2015), or a CAGR of 6.2%. US spending is estimated currently at $430 billion, rising to $560-590 billion by 2020, a CAGR of 5-8%. By comparison, the EU5 (Germany, France, Italy, UK and Spain) is currently $144 billion, rising to $170-200 billion by 2020 (1-4% CAGR). The "pharmerging" countries
    While FDA tries to referee the naming conventions for biosimilars, different factions of the healthcare system weigh in with conflicting priorities
    This past week, New Jersey joined a growing list of states that have codified rules on how pharmacists can substitute a biosimilar for the original, branded biologic; in general, the rules specify that when a substitution (for an "interchangeable" product--more about that later) has been made, the pharmacist needs to report that back to the prescribing physician; and physicians can forbid a substitution by writing "dispense as written" or other language to that effect. This action follows two other biosimilar-prescribing practices
    Trial start-up steps, and overall content management, are Veeva Vault cloud offerings
    Veeva (Pleasonton, CA), which started out in customer relationship management (CRM) for pharma sales reps, has been building out its cloud-based offerings for the pharma industry for several years; two years ago it introduced a trial master-file system (eTMF) supported by Vault, its cloud-based document storage and sharing service. Now, as presented at customer meetings in the US and Europe in the past couple weeks, it is broadening its offerings to include Vault Study Start-Up and Vault RIM (Regulatory Information Management). Study Start-Up is meant to address the steps taken to initiate and engage with clinical trial sites, a time-consuming and
    HHS will hold a webcasted meeting of stakeholders to address pricing issues
    Health and Human Services will hold a Pharmaceutical Forum on Nov. 20 in Washington, with an invitation-only list of speakers and audience members to "share information as to how to address this complex problem" of pharma pricing, with a particular emphasis on "specialty medications [that] represent only 1% of all prescriptions but, in 2014, ... resulted in over 31% of all drug spending." The HHS announcement says that the event will be webcast, and will run most of the day. Forum topics:
    Valeant-Philidor dispute causes a 'mischaracterization' of specialty pharmacy
    The clash between Valeant, investors and regulators over the company's less-than-clear relationship with a specialty pharmacy, Philidor, has generated a response from the National Assn. of Specialty Pharmacy (NASP; Alexandria, VA). The fairly new organization (it came into being in 2012) represents specialty pharmacies (SPs) themselves and distributors as well as manufacturers. "The fact that a company calls itself a specialty pharmacy does not make it so. Simply stated, charging high prices for medications does not define a specialty pharmacy," says a statement released by the organization on Oct. 27. "Specialty pharmacies provide medications and
    Company claims its relationship with Philidor pharmacy violates no law
    On Oct. 26, Valeant management held a highly anticipated investor call to explain the uncertainties surrounding its relationship to a specialty pharmacy, Philidor, which operates across most of the nation, and mostly on behalf of Valeant alone (at least regarding specialty dispensing). Valeant has been making headlines regularly for the past several weeks, most recently after a report from an acknowledged short seller highlighting the company's dealings with Philidor; cumulatively, Valeant's stock value has dropped by some $20 billion
    Biennial survey finds growing awareness of information options by consumers
    Patients' trust of information from the pharma industry has doubled--from 9 to 18% of those surveyed--since 2010; but it's still the lowest among competing sources such as pharmacies, hospitals and medical practitioners, with the latter having the highest rating of 49%. That's one of the eyecatching results from the 2015 Survey of Health Care Consumers, conducted by the Deloitte Center for Health Solutions. The survey, based on a statistically grounded cross-section of the US public, looks at overall trends in healthcare consumerism
    While mHealth apps have more than doubled in quantity, industry and healthcare providers are still figuring out what their value is
    Mobile health (mHealth) apps will either revolutionize healthcare or be the latest smartphone/social-media/Internet fad--or, most likely, something in between. Definitions are still fluid: is a jogging distance tracker as medically meaningful as a monitor of drug levels in the bloodstream? The IMS Institute for Health Informatics (Parsippany, NJ), in the update of a 2013 study, uses the WHO definition: "medical and public health practice supported by mobile devices such as mobile phones, patient monitoring devices, personal digital assistants (PDAs), and other wireless devices," which encompasses many wellness or
    Kansas physicians love their rep visits; Wisconsinites, not so much...
    The 2015 AccessMonitor, a proprietary data source of ZS Associates (Evanston, IL) shows a continued slide in rep access--now the majority (53%) of physicians are "access restricted," which ZS defines as meeting with 31-70% of reps who call on them. The 2014 figure was 49%; in 2008, the first year ZS began studying the topic, only 23% of physicians restricted access. This trend is well known in the industry, but ZS ferrets out some factors that are driving access down: one is health system consolidation. ZS compared 20 metro markets
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the November/December 2015 Issue now - It's Free!
While temperature-controlled components advance, service providers are identifying innovative refinements to basic shipping services
Pharmaceutical Commerce sat down with George Barrett, chairman and CEO at Cardinal Health. Here's what he had to say.
Even with legislative incentives, pharma manufacturers struggle to cost-justify pediatric innovation  continued >
European experience to date indicates a changing perspective on biosimilar pricing  continued >
The right studies at the right time in the right way to meet real-world evidence needs  continued >
Packaging-line engineers are going into overdrive as industry gets ready for the 2017 unit-serialization mandate  continued >
Contract development and manufacturing organizations (CDMOs) want to be more reliable business partners to pharma  continued >
Cold Chain 2015 Directory
Facility manages clinical trial supply, storage, packaging and distribution 
  |     |     |     |     |     |  
©2015 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.